Imatinib has revolutionized the treatment of chronic myelogenous leukemia (CML). Given
the high rates of complete cytogenetic remission achieved with imatinib therapy, molecular …

Molecular monitoring of BCR–ABL transcript levels by real-time quantitative PCR is
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …

Chronic myeloid leukemia (CML) results from expression of the constitutive tyrosine kinase
activity of the Bcr-Abl oncoprotein. Imatinib, a tyrosine kinase inhibitor (TKI), is highly …

Imatinib mesylate, binding to the inactive conformation of Bcr‐Abl tyrosine kinase and
suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic …

The role of molecular monitoring for patients with chronic myeloid leukemia (CML) is
multifaceted. Milestone measurements up to 18 months of first-line imatinib therapy are …

With the progress of chronic myeloid leukemia (CML) therapy, the molecular tools used to
diagnose and monitor patients have become sophisticated. Despite this, a complete …

In imatinib-treated chronic myeloid leukemia (CML), secondary drug resistance is often
caused by mutations in the BCR-ABL kinase domain (KD). As alternative therapies are …

BCR-ABL kinase mutations may confer resistance to imatinib in patients with chronic
myeloid leukemia (CML), and may predict a poor outcome. We investigated whether rises in …

Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia
(CML) are the main mechanism of acquired resistance. The early detection of mutations …

Residual disease in chronic myeloid leukemia patients may be assessed by various
molecular methods. After imatinib treatment a significant proportion of patients achieve …